Mavacamten

Mavacamten is a novel, first-in-class oral medication approved by the US Food and Drug Administration (FDA) as an allosteric modulator of cardiac myosin ATPase to treat obstructive hypertrophic cardiomyopathy (HCM) in patients. This medication is currently indicated for treating adults with symptomatic heart failure classified as New York Heart Association (NYHA) class II and III secondary to obstructive HCM and is aimed to improve functional capacity and alleviate symptoms.